No Data
Shareholders of He Family Ophthalmology (301103.SZ), Meixin Fund and Pengxin Fund, have collectively reduced their Shareholding by 0.6851 million shares.
He Shi Ophthalmology (301103.SZ) announced that the Shareholders Meixin Fund and Pengxin Fund have concluded their shareholding plans ahead of schedule, total...
He Eye Hospital (301103.SZ) issued a pre-loss announcement, expecting a net loss of 20.5 million yuan to 30.75 million yuan for the fiscal year 2024, turning from profit to loss.
He Eye Hospital (301103.SZ) released its performance forecast for 2024, the company expects that for the year 2024, the net profit attributable to...
Ho\'s Ophthalmology: 2024 performance forecast
He Eye Hospital (301103.SZ): Expansion prefers economically developed regions.
Gelonghui reported on January 14 that He’s Ophthalmology (301103.SZ) stated on the investor interaction platform that the company's preferred areas for expansion are economically developed regions, focusing on JING-JIN-JI, the Chengyu city cluster, and the CNI Zhujiang Index, with a focus on expanding consumer Medical services through a combination of self-built and franchise chain models.
Express News | He family ophthalmology, Moutai Zhaohua fund and others have established a health technology industry development fund.
Heshi Ophthalmology (301103.SZ): Currently, the total revenue of hospitals outside the province has increased year-on-year, but it has not yet passed the incubation period.
On November 20th, Gelonghui reported that He’s Ophthalmology (301103.SZ) recently expressed during investor relations activities that the total revenue of hospitals outside the province has seen a year-on-year increase, but has not yet passed the cultivation period. Once the number of patient visits reaches a certain scale, the profit contribution of hospitals outside the province will also see a significant increase.